Key result
A 1-SD increase in log-transformed total adiponectin was associated with higher all-cause mortality (HR 1.09; 95% CI 1.03-1.16; p=0.004), an effect restricted to those with high NT-proBNP.
Why the study?
NT-proBNP has been hypothesized to explain the paradoxical association between adiponectin and cardiovascular and all-cause mortality, prompting examination of potential heterogeneities by NT-proBNP and other clinical covariates.
Is higher adiponectin associated with increased cardiovascular disease risk and mortality, and is this modified by NT-proBNP levels?
Cohort
Is higher adiponectin associated with increased cardiovascular disease risk and mortality, and is this modified by NT-proBNP levels?
The paradoxical association between higher adiponectin levels and increased mortality appears to be driven by underlying cardiac dysfunction, as indicated by high NT-proBNP levels.
Answers are grounded in this paper and cite their sources.
NT-proBNP may modify adiponectin-mortality associations; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND AND AIMS: NT-proBNP has been hypothesized as a possible explanation for the paradoxical association between adiponectin and cardiovascular and all-cause mortality. We examined the heterogeneities by NT-proBNP, sex, BMI, smoking status, hypertension and diabetes status in the association between adiponectin and cardiovascular disease risk and mortality. METHODS AND RESULTS: We used a case-cohort design nested within the EPIC-Heidelberg cohort, including 1387 incident cases of myocardial infarction or stroke, 582 deaths from cardiovascular causes and 2352 total deaths. We estimated hazard ratios for the association between 1SD increase in log-transformed total adiponectin levels and cardiovascular disease risk, cardiovascular mortality and mortality using Prentice-weighted Cox-proportional hazard models and assessed heterogeneity of the associations across strata of covariates. Overall, adiponectin was significantly associated with all-cause mortality [HR = 1.09, 95% CI: 1.03-1.16, p = 0.004]. The association with cardiovascular mortality did not reach statistical significance [1.10 (0.99-1.37), p = 0.073]. There was significant heterogeneity by NT-proBNP in the association between total adiponectin and all-cause mortality (phet = 0.019) such that significant increase in hazards of mortality were restricted to participants in the highest tertile of NT-proBNP. Among these participants, adiponectin showed a dose-response relationship with total mortality such that; compared to participants in the lowest quintile, those in the third, fourth and fifth were at 1.22 (0.87-1.70), 1.50 (1.07-2.11), and 1.59 (1.15-2.21) higher hazards of mortality respectively. CONCLUSIONS: Significant association between adiponectin and mortality was only observed in the context of high NT-proBNP. Our findings provide further support for hypothesis that NT-proBNP may explain the adiponectin paradox.
No takes yet. Share an insight, caveat, or question.
Mukama et al. (2023) conducted a cohort in Cardiovascular disease and mortality. Adiponectin levels was evaluated on All-cause mortality (HR 1.09, 95% CI 1.03-1.16, p=0.004). A 1-SD increase in log-transformed total adiponectin was associated with higher all-cause mortality (HR 1.09; 95% CI 1.03-1.16; p=0.004), an effect restricted to those with high NT-proBNP.
Synapse has enriched 10 related papers. Consider them for comparative context: